NAMSA is pleased to announce the availability of the Bone Morphogenetic Protein 2 (BMP-2) assay to a comprehensive breadth of solutions for Demineralized Bone Matrix (DBM) testing. This in vitro, enzyme-linked immunosorbent assay (ELISA), is used to determine the ability of DBM to induce bone formation by providing a semi-quantifiable measurement of osteoinductive potential.
NAMSA has extensive experience with Class II and Class III, orthopedic, spinal, and orthobiologic devices, as well as cell, tissue and tissue-based products regulated by 21 CFR Part 1271 and Section 361 of the Public Health Service Act. Our testing, pre-clinical, consulting, and clinical research associates include experienced scientists and professionals with universal knowledge of the medical device industry.
This additional offering will allow us to better serve our clients and meet their diverse needs with DBM lot release testing. To learn more about our comprehensive breadth of solutions for tissue and tissue-based products, please reach out to us at namsa.com/contact-us. One of our Project Development Advisors will be happy to assist you and determine how NAMSA can help get your product to market.